LAVA Therapeutics’ (LVTX) “Neutral” Rating Reiterated at HC Wainwright

HC Wainwright reaffirmed their neutral rating on shares of LAVA Therapeutics (NASDAQ:LVTX) in a report issued on Thursday morning, Marketbeat reports. They currently have a $1.50 price objective on the stock, down from their previous price objective of $2.00.

Several other equities research analysts have also recently issued reports on the stock. Leerink Partnrs cut shares of LAVA Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Thursday, December 12th. Leerink Partners reaffirmed a “market perform” rating and set a $2.00 price target (down from $11.00) on shares of LAVA Therapeutics in a report on Thursday, December 12th. JMP Securities reissued a “market perform” rating and set a $6.00 target price on shares of LAVA Therapeutics in a research report on Wednesday, December 11th. Finally, Citizens Jmp downgraded LAVA Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, December 11th. Five investment analysts have rated the stock with a hold rating, According to MarketBeat, LAVA Therapeutics presently has an average rating of “Hold” and a consensus target price of $3.17.

LAVA Therapeutics Trading Down 4.4 %

NASDAQ:LVTX opened at $1.29 on Thursday. LAVA Therapeutics has a 12-month low of $0.85 and a 12-month high of $6.47. The firm has a market cap of $33.91 million, a PE ratio of -1.25 and a beta of 0.57. The stock has a fifty day moving average price of $0.99 and a 200 day moving average price of $1.44.

LAVA Therapeutics (NASDAQ:LVTX) last announced its quarterly earnings data on Tuesday, December 10th. The company reported ($0.46) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.35) by ($0.11). Equities analysts forecast that LAVA Therapeutics will post -1.13 EPS for the current year.

Hedge Funds Weigh In On LAVA Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the stock. Virtu Financial LLC purchased a new stake in LAVA Therapeutics during the third quarter worth about $32,000. BNP Paribas Financial Markets acquired a new stake in shares of LAVA Therapeutics during the 4th quarter valued at approximately $40,000. Finally, Sanofi purchased a new stake in shares of LAVA Therapeutics during the 4th quarter worth approximately $1,825,000.

About LAVA Therapeutics

LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients.